New Delhi, May 20 : Eris Lifesciences Limited , an Indian branded formulations manufacturing company, today announced its earnings for the quarter and full year ended March 31, 2026.
Q4 and FY2026 Key Financial Highlights:
- DBF business revenue growth of 12% YoY in Q4 and 11% YoY in FY26 – EBIDTA margin 37%
- Consolidated Revenue growth 7% YoY in Q4 and 8% YoY in FY26 – EBIDTA margin 36%
- Consolidated Q4 PAT Rs. 279 Cr with a 174% growth, FY26 PAT Rs. 648 Cr, with a 73% growth
- Net debt as of March 31, 2026, stood at Rs. 2,255 Cr
Commenting on the results, Mr. Amit Bakshi, Chairman & Managing Director of Eris Lifesciences Ltd, said,
“Our Domestic Formulations business delivered a 11% revenue growth in FY26 with a 12% EBIDTA growth and industry leading EBIDTA margin of 37%. Our Insulins franchise has outpaced market growth by 5x in FY26 with a market share expansion from 12% to 16%. Our GLP brand Sundae has gotten off to a strong start, which reflects the present standing of the company in the Injectable Diabesity space. Sundae ranks #1 by volume (among injectables) in its very first month of launch, which validates our thesis of being able to leverage our Insulins platform to secure a strong position in the GLP segment.”
